BGL Announces the Sale of Lowenco to Impilo and SHS

Brown Gibbons Lang & Company (BGL), a leading investment banking and financial advisory firm, is pleased to announce the sale of Lowenco A/S (Lowenco), a leading manufacturer of ultra-low temperature (ULT) storage solutions for the pharma industry, to Impilo and SHS. BGL’s Healthcare & Life Sciences investment banking team initiated the transaction and acted as the exclusive financial advisor to Lowenco. The specific terms of the transaction were not disclosed.

Founded in 2013 and headquartered in Vamdrup, Denmark, Lowenco is a leading manufacturer of large-scale ULT storage solutions for biotech and pharmaceutical companies. The company’s unique modular solutions have been developed under the brand names LSSU and CON20, with a steadily increasing R&D pipeline and a growing global customer base. Lowenco delivers its custom solutions worldwide, wherever GMP guidelines are followed.

The company is well-positioned to continue addressing the increasing demand for large scale ULT storage solutions, underpinned by the strong underlying growth in biopharma volumes, leveraging its unique customer value proposition that is centered around superior quality, performance and service, significantly lower cost of ownership, and leading energy efficiency. Following the transaction, Lowenco’s management team will remain intact, led by CEO Mikael Hoier, who has been part of the management team since 2017.

Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. The acquisition of Lowenco marks Impilo’s fourth investment in Denmark. SHS, based in Tübingen, Germany, specializes in healthcare investments and is currently investing from its fifth fund, which was launched in 2018.